Dr. Pier Vincenzo Piazza is Co-Founder and CEO of Aelis Farma, a biotechnology company targeting disorders induced by external cannabinoids, the chemical compounds contained in cannabis.
These cannabis-related disorders include addiction, cannabinoid hyperemesis syndrome, and psychosis and are related to how the CB1 receptor is stimulated by cannabinoids.
Pier says, "The CB1 is a very interesting receptor for several reasons. First of all, is one of the neurotransmitter receptors the most expressed in the brain. So in your brain, one of the neurotransmitter receptors that you have the most of is the CB1 that is consequently involved in a large number of functions."
"Another thing that is interesting about these receptors is that people are all different, you, me, even your son and daughter are different. However, we all share something that is absolutely identical in all of us--that is, the CB1 because the receptor CB1 has no variance between human beings. It's one of the few receptors that is 100% identical in everyone."
Listen to the podcast and download the transcript to gain insight into the new molecules being developed as inhibitors of bad activity of the CB1 receptor. Listen to Podcast